170887 ⎘
Detection or diagnosis of diseases; Pediatrics Cystic fibrosis
EVALUATION OF PATIENTS WITH CYSTIC FIBROSIS USING SWEAT
#2METHOD AND KIT FOR THE EARLY DETECTION OF SEPSIS
#3METHODS OF DETECTING LIPOARABINOMANNAN AND DIAGNOSING NONTUBERCULOSIS MYCOBACTERIAL INFECTION
#4METHODS OF MAKING AND USING LIVER CELLS
#5CYSTIC FIBROSIS URINE TEST
#6Method for the qualitative and quantitative detection of alginate oligomers in body fluids
#7Rapid quantitative test to diagnose polycystic kidney disease
#8COMPOSITIONS AND METHODS FOR TREATMENT OF LUNG FUNCTION
#9Methods for high-content drug screening
#10Detection of cleavage activity of an enzyme
#11COMPOSITIONS AND METHODS FOR TREATMENT OF LUNG FUNCTION
#12Cystic fibrosis transmembrane conductance regulator gene mutations
#13METHODS OF MEASURING UBIQUITIN-LIKE MODIFICATIONS
#14Methods for Diagnosing and Treating Subjects for Pulmonary Exacerbation
#15Binding compound and uses thereof
#16ALX receptor ligands define a biochemical endotype for inflammation-based diseases
#17Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells
#18Mutations associated with cystic fibrosis
#19Modified cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides with increased stability and uses thereof
#20METHODS OF IDENTIFYING CFTR MODULATORS
#21Method for the Diagnosis of Cystic Fibrosis
#22Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
#23Compositions and methods for treatment of lung function
#24Cystic fibrosis transmembrane conductance regulator gene mutations
#25Risk Factors of Cigarette Smoke-Induced Spriometric Phenotypes
#26ADAM12 inhibitors and their use against inflammation-induced fibrosis
#27Mutations associated with cystic fibrosis
#28Metabolite panel for improved screening and diagnostic testing of cystic fibrosis
#29Methods for diagnosing and treating subjects for pulmonary exacerbation
#30Compounds for treatment of cystic fibrosis
#31POTENTIATOR-CORRECTOR COMBINATIONS USEFUL IN THE TREATMENT OF CYSTIC FIBROSIS
#32Cystic fibrosis transmembrane conductance regulator gene mutations
#33Modulators of ATP-binding cassette transporters
#34Detection of cleavage activity of an enzyme
#35MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
#36RATIOMETRIC ASSAY FOR HYDROLYTIC ENZYME QUANTIFICATION
#37Mutations associated with cystic fibrosis
#38A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL
#39COMPOUNDS AND METHODS FOR INHIBITING CIF VIRULENCE FACTOR
#40Rapid quantitative assay to measure CFTR function in a primary intestinal culture model
#41ADAM12 inhibitors and their use against inflammation-induced fibrosis
#42Mutations associated with cystic fibrosis
#43Treating protein folding disorders with small molecule CFTR correctors
#44Method for the diagnosis and/or prognosis of granulocyte-related inflammatory states
#45Methods for Treating Inflammation and Oxidative Stress Related Diseases
#46Testing of Biofilm for Anti-microbial Agent Susceptibility
#47BIOMARKERS PREDICTIVE OF PROGRESSION OF FIBROSIS
#48BIOMARKERS FOR PROGNOSES OF PULMONARY DISEASES
#49ADAM12 Inhibitors and Their Use Against Inflammation-Induced Fibrosis
#50Modulators of cystic fibrosis transmembrane conductance regulator
#51Cystic fibrosis transmembrane conductance regulator gene mutations
#52METHODS OF ASSESSING AND TREATING PULMONARY DISEASE
#53Modulators of cystic fibrosis transmembrane conductance regulator
#54CELL LINES EXPRESSING CFTR AND METHODS OF USING THEM
#55METHOD FOR DIAGNOSIS OF CYSTIC FIBROSIS USING KL-6 LEVELS
#56Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
#57Methods for identifying and compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant cystic fibrosis transmembrane conductance regulator
#58Mutations associated with cystic fibrosis
#59METHODS OF QUANTIFYING BIOMARKERS
#60Biomarkers For Prognosis of Pulmonary Diseases
#61SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS
#62Cystic fibrosis transmembrane conductance regulator gene mutations
#63CHARACTERIZATION OF IL-17F AND IL-17R INTERACTIONS
#64Modulators of cystic fibrosis transmembrane conductance regulator
#65METHODS FOR IDENTIFYING AGENTS AND THEIR USE FOR THE PREVENTION OR STABILIZATION OF FIBROSIS
#66Methods for Treatment and Diagnosis of Pulmonary Diseases Based on the Expression of SERCA2 Protein
#67COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH
#68Method for measuring activity of a specific fraction of albumin
#69Methods for treating fibrosis using CRP antagonists
#70Cystic fibrosis transmembrane conductance regulator gene mutations
#71Cystic fibrosis transmembrane conductance regulator gene mutations
#72Compositions and Methods for the Treatment of Cystic Fibrosis and other Pulmonary Disorders
#73CFTR polypeptides methods to overcome biosynthetic misprocessing
#74Method of detecting the cystic fibrosis transmembrane conductance regulator (CFTR) at cell exterior
#75Method of identifying markers diagnostic of disease and uses therefor in the diagnosis of cancer
#76Regulation of cell surface proteins
#77Use of IL-17F in diagnosis and therapy of airway inflammation
#78Compounds acting at the centrosome
#79Method of treating respiratory disorders and airway inflammation
#80Mammalian cell surface DNA receptor
#81Method for detecting diseases that are associated with defects of cystic fibrosis transmembrane conductance regulator (CFTR) protein
#82Method for assessment of cystic lung fibrosis